A good surgical result matters. So does everything around it. What a patient does before and after a procedure shapes how the body heals, and that’s where a lot of outcomes are won or lost.
That’s why Florida Spine Associates now offers patients access to Day Zero, a biologic derived from perinatal tissue, as part of a broader spine and orthopedic care plan.
“We look at recovery as part of the procedure, not something that happens after it,” said orthopaedic spine surgeon Milad Alam, MD. “Choosing partners who meet the same standards we hold ourselves to is part of that.”
Why Sourcing Comes First
Before any product reaches a patient, it has to clear a high bar. Florida Spine Associates is selective about partners, and the checklist is specific:
- Products made in FDA-registered labs that meet strict manufacturing standards
- Ethically sourced perinatal tissue, with documented donor screening
- Third-party testing and verified quality controls
- Full transparency in how products are handled and supplied
Day Zero checks every box and strictly adheres to current Good Manufacturing Practices (cGMP), and ISO 7 standards as required by FL SB1768. The manufacturing process is designed to preserve naturally occurring components of the donated tissue.
What sets ZEO ScientifiX apart isn’t just the product, it’s the operation behind it. Every batch is processed in FDA-registered labs with quality checks built into each stage of production, so it can be traced from donor screening through final release.
ZEO also invests in physician education, so providers understand the science, sourcing, and proper clinical use of its products before they ever reach you. That commitment is backed by an academic partnership with Nova Southeastern University, one of the few universities in the country that graduates both MDs and DOs, inside a $100 million collaborative research center.
Together, these are the markers of a company built for the long term, not one chasing a trend in regenerative medicine.
What the Research Shows
Regenerative medicine covers two related but different things:
- Mesenchymal stem cells (MSCs), which are living cells
- Exosomes which are the tiny particles those cells release to communicate with each other and coordinate repair
In general terms, exosomes work by carrying cargo, proteins, RNA fragments, and other signaling molecules, from the cell that released them to nearby cells, where that cargo can influence inflammation and support tissue repair.
Day Zero is built around the exosome category. It contains no live cells of any kind. It carries the signaling particles cells produce, not the cells themselves, which is also why it’s regulated differently than a stem cell product.
Stem cell research is its own separate, well-established field. One recent review looked at umbilical cord-derived MSCs across a range of regenerative applications. Florida Spine Associates doesn’t offer MSC therapy. Day Zero’s research base sits in the exosome side of the field specifically.
Interest in amniotic-derived biologics for back pain is growing. A 2025 commentary in Interventional Pain Medicine described an exploratory study of epidural amniotic fluid injections for chronic low back pain, where patients receiving image-guided injections reported meaningful improvements in both pain and function.
The commentary’s authors pointed to why amniotic-derived products draw interest in the first place: their anti-inflammatory, immune-privileged properties, without the added regulatory complexity of a cell-based therapy.
That study evaluated a different amniotic fluid product, not Day Zero specifically, and the authors were upfront that it’s early research, with larger, controlled studies still needed. It’s a promising early signal for the category Day Zero belongs to.
Day Zero is not a stem cell product. It’s an exosome-based biologic, meaning it’s a-cellular: it carries naturally occurring proteins and signaling particles without the added complexity of live-cell therapies. Because it’s cell-free, it’s regulated differently than stem cell treatments, though both fall under the same Florida framework for orthopedic, wound care, and pain management use.
A Trusted Partner, Not a Trend
“I have been impressed with the patient reported outcomes that I have seen thus far using exosomes as an alternative to traditional steroids,” said orthopaedic spine surgeon Robert Norton, MD. “Although exosomes are in early stages of clinical studies, the field of regenerative medicine is growing and becoming more mainstream, which I think is a great thing for medicine overall.”
Whether Day Zero makes sense for a specific patient is decided in a one-on-one conversation with a physician, not through general reading or self-assessment.
Florida Spine Associates chose ZEO ScientifiX because the people behind it have long track records in regulated healthcare.
That kind of history matters when evaluating a newer therapy, because the question isn’t just whether something works in a lab. It’s whether the company behind it is built to stand behind its product over time.
This article is for general informational and educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Individualized treatment decisions are made solely between a patient and their provider. Some products referenced may be considered investigational and have not been approved by the FDA for the uses discussed. Product availability is subject to applicable state law; current availability is limited to Florida and Utah under Florida Senate Bill 1768 (FS §458.3245, FS §459.0127).
For more information about Zeo Scientific and its products please review the video library.